Oral drug approved for relapsing multiple sclerosis

Thompson, Cheryl A.
November 2010
American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788
Academic Journal
The article reports on the approval of Novartis AG's fingolimod, a podrug of sphingosine 1-phosphate receptor modulator, for treating patients with relapsing forms of multiple sclerosis by the U.S. Food & Drug Administration (FDA). It looks at how such drug aids in reducing the severity of multiple sclerosis. It notes the adverse side effects in patients who take 0.5 milligram (mg) per day of fingolimod.


Related Articles

  • Reexamining the evidence for inpatient glucose control: New recommendations for glycemic targets. Moghissi, Etie S. // American Journal of Health-System Pharmacy;8/15/2010 Supplement, Vol. 67, pS3 

    Purpose. To review the risks of hyperglycemia in hospitalized patients, data supporting the benefits of treating hyperglycemia, and recommendations from the 2009 American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on the management of inpatient...

  • GILENYA for relapsing forms of multiple sclerosis (MS). Discover your POSSIBILITIES.  // Momentum (19403410);Fall2012, Vol. 5 Issue 4, p28 

    The article discusses the availability of the Gilenya, a prescription medicine indicated to treat relapsing forms of multiple sclerosis (MS) in adults, from Novartis AG and includes important safety information and its serious side effects.

  • First oral thrombin inhibitor enters market: Drug does not require clinicians to monitor INR. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p1974 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the marketing of dabigatran etexilate or Pradaxa. According to Boehringer Ingelheim Pharmaceuticals Inc., the drug prevents stroke and systematic embolism in patients with nonvalvular atrial fibrillation. It...

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788 

    The article offers information on the use of new drugs for specific treatments including dexamethasone intravitreal implant for noninfectious ocular inflammation, combination of drospirenone, ethinyl estradiol, and levomefolate calcium tablets and levomefolate calcium tablets for pre-menstrual...

  • A New Era: New Drugs, New Options, New Risks. King, Martha // Momentum (19403410);Spring2011, Vol. 4 Issue 2, p21 

    The article offers updates on multiple sclerosis (MS) management. It cites the case of Melissa Losasso who had side effects after taking drugs and a weekly injection under a clinical trial. The safety issues about the new drugs being developed for MS are discussed, including Gilenya and Tysabri...

  • FORMULATION AND EVALUATION OF ETHOSOMES OF PLUMERIA INDICA LINN. FLOWERS. Rajput, Ankita; Malviya, Jitendra; Prajapati, Sandeep; Shriwas, Shweta; Dwivedi, Sumeet; Dubey, Raghvendra // International Journal of Pharmacy & Life Sciences;Sep2016, Vol. 7 Issue 9, p14 

    The number of products based on new drug delivery systems has significantly increased in the past few years, and this growth is expected to continue in the near future. These biopharmaceuticals present challenges to drug delivery scientists because of their unique nature and difficulty in...

  • FDA APPROVES INTERFERON BETA-IB FOR THE TREATMENT OF MULTIPLE SCLEROSIS. Naccari, Christopher // CNS Spectrums: The International Journal of Neuropsychiatric Med;Sep2009, Vol. 14 Issue 9, p464 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) on the use of interferon beta-1B as treatment for multiple sclerosis. It offers information on the recommended dosage and subcutaneous injection of the drug, and the value of rotating injection sites. It also...

  • FDA Approves AVONEX(r) PEN(tm) and Dose Titration Regimen.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article provides information on an announcement made by Biogen Idec Inc., regarding the approval of its drug AVONEX (®) PEN (™) and Dose Titration Regimen by the U.S. Food and Drug Administration. AVONEX PEN is the first intramuscular (IM) autoinjector approved for the treatment of...

  • NEW DRUGS.  // Drug Topics;6/5/2006, Vol. 150 Issue 11, p45 

    The article reports on the approval of new drug solodyn extended-release tablets from Medicris Pharmaceutical Corp. by the U.S. Food and Drug Administration in 2006. Solodyn is an oral minocycline indicated for once-daily medication to treat inflammatory wounds of non-nodular moderate to severe...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics